- Home
- SBRA vs PTCT Comparison
SBRA vs PTCT Comparison
Compare SBRA & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- PTCT
- Stock Information
- Founded
- SBRA 2010
- PTCT 1998
- Country
- SBRA United States
- PTCT United States
- Employees
- SBRA N/A
- PTCT N/A
- Industry
- SBRA Real Estate Investment Trusts
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- SBRA Real Estate
- PTCT Health Care
- Exchange
- SBRA Nasdaq
- PTCT Nasdaq
- Market Cap
- SBRA 4.6B
- PTCT 4.1B
- IPO Year
- SBRA N/A
- PTCT 2013
- Fundamental
- Price
- SBRA $19.13
- PTCT $59.10
- Analyst Decision
- SBRA Buy
- PTCT Buy
- Analyst Count
- SBRA 8
- PTCT 14
- Target Price
- SBRA $20.63
- PTCT $67.00
- AVG Volume (30 Days)
- SBRA 2.3M
- PTCT 1.4M
- Earning Date
- SBRA 10-30-2025
- PTCT 11-06-2025
- Dividend Yield
- SBRA 6.30%
- PTCT N/A
- EPS Growth
- SBRA 236.12
- PTCT N/A
- EPS
- SBRA 0.76
- PTCT 7.72
- Revenue
- SBRA $734,008,000.00
- PTCT $1,764,929,000.00
- Revenue This Year
- SBRA $6.49
- PTCT $119.89
- Revenue Next Year
- SBRA $7.50
- PTCT N/A
- P/E Ratio
- SBRA $25.08
- PTCT $7.91
- Revenue Growth
- SBRA 10.21
- PTCT 96.00
- 52 Week Low
- SBRA $15.60
- PTCT $31.80
- 52 Week High
- SBRA $20.03
- PTCT $62.18
- Technical
- Relative Strength Index (RSI)
- SBRA 53.80
- PTCT 66.59
- Support Level
- SBRA $18.81
- PTCT $57.47
- Resistance Level
- SBRA $19.29
- PTCT $62.18
- Average True Range (ATR)
- SBRA 0.34
- PTCT 2.13
- MACD
- SBRA -0.05
- PTCT 0.76
- Stochastic Oscillator
- SBRA 40.95
- PTCT 77.85
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.